Concerns Rise Over Antipsychotic Misuse in Nursing Homes
Berlin – Recent reports from the Department of Health and Human Services (HHS) Office of Inspector General (OIG) have revealed troubling patterns of inappropriate diagnoses and medication practices within nursing homes across the United States. The findings, released in March 2026, indicate that some facilities are incorrectly diagnosing residents with schizophrenia to justify the prescription of antipsychotic drugs, often not for therapeutic benefit but for operational convenience. This practice raises serious questions about resident care, quality of life, and the integrity of the nation’s long-term care system. The reports highlight a concerning trend of prioritizing staff management over the well-being of vulnerable individuals.
The HHS OIG’s investigation, based on a review of 40 nursing home inspections completed by the Centers for Medicare & Medicaid Services (CMS), uncovered instances where facilities deliberately added schizophrenia diagnoses to resident records. This manipulation was reportedly done to exclude those residents from quality measures that track antipsychotic drug employ, a metric that directly impacts a facility’s CMS star rating. A lower antipsychotic drug use rate generally translates to a higher star rating, incentivizing facilities to artificially lower their reported numbers. This manipulation undermines the transparency and accuracy of the CMS star rating system, which is relied upon by families when selecting care for their loved ones.
Diagnoses Used to Circumvent Safeguards
The OIG reports further detailed how medical directors within some nursing homes made inappropriate schizophrenia diagnoses to justify prescribing antipsychotic medications. These drugs, while sometimes necessary for individuals with genuine psychotic disorders, carry significant risks, including increased risk of stroke, metabolic changes, and even premature death, particularly in elderly populations. The reports suggest that facilities were exploiting these diagnoses not only to improve their CMS ratings but also to circumvent Medicare safeguards designed to protect residents from unnecessary medication. These safeguards are in place to ensure that antipsychotic drugs are only prescribed when medically necessary and with appropriate monitoring.
The practice of misdiagnosis and inappropriate medication use directly compromised resident care. While the reports do not detail specific cases of harm, they strongly imply that residents were subjected to potentially dangerous medications without a legitimate medical need. This raises ethical and legal concerns, potentially opening facilities up to liability and further scrutiny from regulatory bodies. The OIG’s findings underscore the need for more robust oversight and enforcement of regulations governing medication management in nursing homes.
CMS Star Ratings and Quality Measures
The CMS star rating system is a crucial tool for consumers seeking information about the quality of nursing homes. The system assigns a rating from one to five stars, with five stars representing the highest quality of care. A key component of this rating is a measure of antipsychotic drug use in long-stay residents, as high rates of antipsychotic use can indicate poor care and inappropriate medication practices. The CMS Nursing Home Quality Initiative aims to improve the quality of care in nursing homes by promoting best practices and holding facilities accountable for their performance. By artificially manipulating this metric through inaccurate diagnoses, facilities are misleading consumers and undermining the integrity of the system.
The OIG’s findings are particularly concerning given the vulnerability of nursing home residents. Many residents have cognitive impairments, making them less able to advocate for themselves or report inappropriate care. This places a greater responsibility on facilities and their staff to act in the best interests of their residents. The reports suggest that, in some cases, this responsibility was neglected, with staff prioritizing operational efficiency over resident well-being.
Value-Based Care and Regulatory Modernization
These findings arrive as the healthcare industry continues to transition towards value-based care models, which emphasize quality of care over quantity of services. The HHS OIG recently issued a final rule designed to advance this transition and modernize the regulatory framework. This rule aims to incentivize providers to deliver high-quality, cost-effective care. However, the OIG’s report on antipsychotic misuse highlights the challenges of implementing value-based care in a setting where incentives may be misaligned and where oversight is inadequate. The rule seeks to promote better outcomes and reduce unnecessary costs, but its success depends on robust enforcement and a commitment to ethical practices.
Increased Scrutiny and Fraud Takedowns
The HHS OIG’s investigation into nursing home practices is part of a broader effort to combat healthcare fraud and abuse. In a separate action, the Department of Justice announced a record-setting national healthcare fraud takedown in early 2026, targeting schemes involving a wide range of fraudulent activities, including billing fraud and improper prescribing practices. The National Law Review reported on this takedown, noting that it involved hundreds of defendants and billions of dollars in alleged losses. This increased scrutiny of the healthcare industry signals a commitment to protecting taxpayers and ensuring that healthcare resources are used appropriately.
The recent focus on healthcare fraud and abuse, coupled with the OIG’s findings on antipsychotic misuse, underscores the need for continued vigilance and proactive oversight. The HHS OIG plays a critical role in identifying and addressing vulnerabilities in the healthcare system, and its reports serve as a valuable resource for policymakers, regulators, and consumers alike. The agency’s work helps to ensure that healthcare resources are used effectively and that patients receive the quality of care they deserve.
What Happens Next?
The HHS OIG has recommended that CMS take steps to strengthen oversight of nursing home medication practices and to ensure the accuracy of data reported through the CMS star rating system. CMS has not yet publicly responded to these recommendations, but it is expected to announce further actions in the coming months. The agency is also likely to increase its scrutiny of nursing home inspections and to conduct more targeted investigations into facilities with high rates of antipsychotic drug use. Families and advocates for nursing home residents are encouraged to report any concerns about inappropriate care to their local ombudsman program or to the HHS OIG directly.
The issue of antipsychotic misuse in nursing homes is a complex one with no easy solutions. It requires a multi-faceted approach that includes stronger regulations, more robust oversight, and a greater emphasis on person-centered care. The goal is to ensure that nursing home residents receive the care and respect they deserve, and that their rights are protected. The ongoing investigations and regulatory changes represent a step in the right direction, but continued vigilance and advocacy will be essential to achieving lasting improvements.
Have your say: What steps do you think are most crucial to address the issue of antipsychotic misuse in nursing homes? Share your thoughts in the comments below, and please share this article with your network to raise awareness about this vital issue.